Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | Zendy

Oliver Sartor | Zendy; Johann S. de Bono | Zendy; Kim N. | Zendy; Karim Fizazi | Zendy; Ken Herrmann | Zendy; Kambiz Rahbar | Zendy; Scott T. Tagawa | Zendy; Luke T. Nordquist | Zendy; Nitin Vaishampayan | Zendy; Ghassan ElHaddad | Zendy; Chandler H. Park | Zendy; Tomasz M. Beer | Zendy; Alison Armour | Zendy; Wendy J. Pérez-Contreras | Zendy; Michelle DeSilvio | Zendy; Euloge Kpamegan | Zendy; Germo Gericke | Zendy; Richard A. Messmann | Zendy; Michael J. Morris | Zendy; Bernd J. Krause | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Oliver Sartor,

Johann S. de Bono,

Kim N.,

Karim Fizazi,

Ken Herrmann,

Kambiz Rahbar,

Scott T. Tagawa,

Luke T. Nordquist,

Nitin Vaishampayan,

Ghassan ElHaddad,

Chandler H. Park,

Tomasz M. Beer,

Alison Armour,

Wendy J. Pérez-Contreras,

Michelle DeSilvio,

Euloge Kpamegan,

Germo Gericke,

Richard A. Messmann,

Michael J. Morris,

Bernd J. Krause

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2107322

Subject(s) - prostate cancer , medicine , castration , oncology , cancer research , prostate , cancer , hormone

Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 ( 177 Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research